Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
Journal Article
| Authors | Alexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, ... |
| Year | 2020 |
| Language | English |
| Journal Name | The Lancet HIV |
Taxonomy Associations
Geographies
-
UN Countries
